{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:15:22Z","timestamp":1777950922680,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiplatelet drugs are conventionally used as treatments because of their anti\u2010coagulation functions. However, their pleiotropic effects are of great significance to the treatment of ischaemic cardiovascular diseases. Many studies have reported that an excessive amount of inflammation driven by tumour necrosis factor (TNF) is closely related to the prevalence of atherosclerosis. As the drug selection criteria and evaluation methods related to the anti\u2010TNF activity of antiplatelet drugs remain limited, our investigation of these drugs should prove beneficial. In this study, we compared the anti\u2010TNF activity of three antiplatelet agents, namely clopidogrel, sarpogrelate, and cilostazol, using the TNF\u2010induced inflammatory mouse model. After the oral administration of these drugs, acute inflammation was induced via injection of lipopolysaccharide (LPS) or D\u2010galactosamine (D\u2010gal) and TNF. Serum TNF levels, and the mRNA and protein expression levels of TNF in mouse heart tissue, macrophage accumulation in aortic lesions, and mouse survival were analysed to compare the anti\u2010TNF effects of the three antiplatelet agents. Of the three antiplatelet agents, cilostazol significantly reduced the different levels under the most effective observation. In addition, cilostazol was found to attenuate the TNF\u2010stimulated phosphorylation of mitogen\u2010activated protein kinase (MAPK) and nuclear factor kappa\u2010light\u2010chain\u2010enhancer of activated B cell (NF\u2010\u03baB) p65 in the aortic vascular smooth muscle cell line, MOVAS\u20101 and the D\u2010gal plus TNF\u2010challenged heart tissue of mouse. Therefore, cilostazol is the most ideal of the three antiplatelet drugs for the treatment of TNF\u2010mediated inflammatory disorders.<\/jats:p>","DOI":"10.1111\/1440-1681.13211","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T10:27:03Z","timestamp":1573554423000},"page":"432-438","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative effectiveness of different antiplatelet agents at reducing TNF\u2010driven inflammatory responses in a mouse model"],"prefix":"10.1111","volume":"47","author":[{"given":"Hae\u2010Ri","family":"Lee","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaco\u2010Immunology Integrated Research Institute of Pharmaceutical Sciences BK21 PLUS Team for Creative Leader Program for Pharmacomics\u2010based Future Pharmacy College of Pharmacy The Catholic University of Korea Bucheon\u2010si Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung\u2010Yeon","family":"Park","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco\u2010Immunology Integrated Research Institute of Pharmaceutical Sciences BK21 PLUS Team for Creative Leader Program for Pharmacomics\u2010based Future Pharmacy College of Pharmacy The Catholic University of Korea Bucheon\u2010si Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young\u2010Jin","family":"Jeong","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco\u2010Immunology Integrated Research Institute of Pharmaceutical Sciences BK21 PLUS Team for Creative Leader Program for Pharmacomics\u2010based Future Pharmacy College of Pharmacy The Catholic University of Korea Bucheon\u2010si Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-7205","authenticated-orcid":false,"given":"Tae\u2010Hwe","family":"Heo","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco\u2010Immunology Integrated Research Institute of Pharmaceutical Sciences BK21 PLUS Team for Creative Leader Program for Pharmacomics\u2010based Future Pharmacy College of Pharmacy The Catholic University of Korea Bucheon\u2010si Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-12-1067"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27196"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/790263"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1995.tb05801.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199001001-00004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03450807"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147929"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.04.023"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.03.016"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0361-y"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.01.006"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2010.12.010"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.02.006"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R600021-JLR200"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20080196"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12280"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2019.1569045"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499335"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1247"},{"issue":"1","key":"e_1_2_7_21_1","first-page":"71","article-title":"Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients","volume":"103","author":"Muhlestein JB","year":"2011","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2015.01.021"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-11-0947"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2018.12.005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/165974"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2018.1542734"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12521"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.6"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.21388"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.104.2.203"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.03.041"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e3181f48987"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.147"},{"key":"e_1_2_7_36_1","first-page":"e22279","article-title":"Clopidogrel reduces lipopolysaccharide\u2010induced inflammation and neutrophil\u2010platelet aggregates in an experimental endotoxemic model","volume":"10","author":"Wang X\u2010L","year":"2018","journal-title":"J Biochem Mol Toxicol"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179221"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.13211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1440-1681.13211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.13211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T04:29:18Z","timestamp":1694147358000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.13211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/1440-1681.13211"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.13211","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"assertion":[{"value":"2019-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}